Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Manufacturer Fines Outlined In Rule, But HRSA Expects To Use Them ‘Very Rarely’

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.


Related Content

340B Pricing, Penalty Alternatives Will Be Reassessed; Final Rule Delayed
Manufacturers Say 340B Penalties Proposal Could Punish Actions Outside Their Control
340B 'Penny Pricing' Policy Draws Manufacturers' Ire
HRSA’s ‘Piecemeal’ Approach To 340B Integrity Rules Draws Manufacturer Objections
ACOs Can’t Tap Into 340B Drug Discounts Provided To Member Safety Net Facilities, HRSA Clarifies
340B Price Setting Policy Should Precede Dispute, Penalty Actions, BIO Urges


What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts